URMC Research Network

Find People
Keyword
Last Name
 
More Search Options

Andrew Goodman

TitleProfessor
InstitutionSchool of Medicine and Dentistry
DepartmentNeurology
AddressUniversity of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 605
Rochester NY 14642
 
 Awards And Honors
1973 - 1974Henry Rutgers Scholar
1974     A.B. with Distinction in Biochemistry
1979     Alpha Omega Alpha
1982 - 1983Chief Neurology Resident
1996     Named in Best Doctors in America: Northeast.
1997     University of Rochester Neurology Resident Faculty Teaching Award
1998 - 1999Chair-elect, Multiple Sclerosis Section  | American Academy of Neurology
1998     Named in Best Doctors in America
1999 - 2000Chair, Multiple Sclerosis Section  | American Academy of Neurology
2001     Inductee, Volunteer Hall of Fame  | US National Multiple Sclerosis Society
2003     Senior Faculty Award  | University of Rochester Department of Neurology
2004     Impact Presentation Award, Congress of the European Committee for Treatment and Research in Multiple Sclerosis
2005     Fellow, American Academy of Neurology
 
 Overview
Andrew D. Goodman, MD is Professor of Neurology, Chief of the Neuroimmunology Unit, and Director of the Multiple Sclerosis Center at the University of Rochester.

Dr. Goodman is a graduate of Rutgers College and the University of Medicine and Dentistry of New Jersey; he did residency training in internal medicine and neurology at Mt. Sinai Medical Center in New York City. He completed a research fellowship in the Neuroimmunology Branch at the National Institutes of Health, Bethesda, Maryland.

Numerous publications reflect his interests in clinical and experimental therapeutics research as well as the immunology and virology of multiple sclerosis. Dr. Goodman has been principal investigator and a member of national and international steering committees for numerous clinical trials of new therapies for multiple sclerosis.

Dr. Goodman is a past Chair of the Multiple Sclerosis Section of the American Academy of Neurology. He has served the National Multiple Sclerosis Society as Deputy Medical Officer, Co-Chair of the Long-term Care Committee, member of the Client Education Committee, and member of the Executive Committee of the National Clinical Advisory Board.

 
 Selected Publications
List All   |   Timeline
  1. Hobart J, Blight AR, Goodman A, Lynn F, Putzki N. Timed 25-Foot Walk: Direct evidence that improving 20% or greater is clinically meaningful in MS. Neurology. 2013 Apr 16; 80(16):1509-17.
    View in: PubMed
  2. Goodman AD, Stone RT. Enhancing neural transmission in multiple sclerosis (4-aminopyridine therapy). Neurotherapeutics. 2013 Jan; 10(1):106-10.
    View in: PubMed
  3. Strober LB, Christodoulou C, Benedict RH, Westervelt HJ, Melville P, Scherl WF, Weinstock-Guttman B, Rizvi S, Goodman AD, Krupp LB. Unemployment in multiple sclerosis: the contribution of personality and disease. Mult Scler. 2012 May; 18(5):647-53.
    View in: PubMed
  4. Samkoff LM, Goodman AD. Symptomatic management in multiple sclerosis. Neurol Clin. 2011 May; 29(2):449-63.
    View in: PubMed
  5. Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010 Oct; 68(4):494-502.
    View in: PubMed
  6. Goodman AD, Hyland M. Dalfampridine in multiple sclerosis. Drugs Today (Barc). 2010 Sep; 46(9):635-9.
    View in: PubMed
  7. Herrmann DN, O'Connor AB, Schwid SR, Da Y, Goodman AD, Rafferty J, Donahue S, Dworkin RH. Broadening the spectrum of controls for skin biopsy in painful neuropathies. Muscle Nerve. 2010 Sep; 42(3):436-8.
    View in: PubMed
  8. Rudick RA, O'Connor PW, Polman CH, Goodman AD, Ray SS, Griffith NM, Jurgensen SA, Gorelik L, Forrestal F, Sandrock AW, E Goelz S. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol. 2010 Sep; 68(3):304-10.
    View in: PubMed
  9. Morrow SA, O'Connor PW, Polman CH, Goodman AD, Kappos L, Lublin FD, Rudick RA, Jurgensen S, Paes D, Forrestal F, Benedict RH. Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult Scler. 2010 Nov; 16(11):1385-92.
    View in: PubMed
  10. Kister I, Chamot E, Bacon JH, Niewczyk PM, De Guzman RA, Apatoff B, Coyle P, Goodman AD, Gottesman M, Granger C, Jubelt B, Krupp L, Lenihan M, Lublin F, Mihai C, Miller A, Munschauer FE, Perel AB, Teter BE, Weinstock-Guttman B, Zivadinov R, Herbert J. Rapid disease course in African Americans with multiple sclerosis. Neurology. 2010 Jul 20; 75(3):217-23.
    View in: PubMed
  11. Ford C, Goodman AD, Johnson K, Kachuck N, Lindsey JW, Lisak R, Luzzio C, Myers L, Panitch H, Preiningerova J, Pruitt A, Rose J, Rus H, Wolinsky J. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler. 2010 Mar; 16(3):342-50.
    View in: PubMed
  12. Mehta LR, McDermott MP, Goodman AD, Schwid SR. A randomized trial of memantine as treatment for spasticity in multiple sclerosis. Mult Scler. 2010 Feb; 16(2):248-51.
    View in: PubMed
  13. Goodman AD, Rossman H, Bar-Or A, Miller A, Miller DH, Schmierer K, Lublin F, Khan O, Bormann NM, Yang M, Panzara MA, Sandrock AW. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology. 2009 Mar 3; 72(9):806-12.
    View in: PubMed
  14. Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009 Feb 28; 373(9665):732-8.
    View in: PubMed
  15. Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology. 2009 Feb 10; 72(6):535-41.
    View in: PubMed
  16. Goodman AD, Brown TR, Cohen JA, Krupp LB, Schapiro R, Schwid SR, Cohen R, Marinucci LN, Blight AR. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology. 2008 Oct 7; 71(15):1134-41.
    View in: PubMed
  17. Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data. Mult Scler. 2008 Apr; 14(3):370-82.
    View in: PubMed
  18. Mehta LR, Samuelsson MK, Kleiner AK, Goodman AD, Anolik JH, Looney RJ, Schwid SR. Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome. Mult Scler. 2008 Apr; 14(3):425-7.
    View in: PubMed
  19. Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. Neurology. 2007 Mar 20; 68(12):939-44.
    View in: PubMed
  20. Schwid SR, Goodman AD, Weinstein A, McDermott MP, Johnson KP. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial. J Neurol Sci. 2007 Apr 15; 255(1-2):57-63.
    View in: PubMed
  21. Goodman AD, Cohen JA, Cross A, Vollmer T, Rizzo M, Cohen R, Marinucci L, Blight AR. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler. 2007 Apr; 13(3):357-68.
    View in: PubMed
  22. Kwon HL, Ortiz B, Swaner R, Shoemaker K, Jean-Louis B, Northridge ME, Vaughan RD, Marx T, Goodman A, Borrell LN, Nicholas SW. Childhood asthma and extreme values of body mass index: the Harlem Children's Zone Asthma Initiative. J Urban Health. 2006 May; 83(3):421-33.
    View in: PubMed
  23. Kinkel RP, Kollman C, O'Connor P, Murray TJ, Simon J, Arnold D, Bakshi R, Weinstock-Gutman B, Brod S, Cooper J, Duquette P, Eggenberger E, Felton W, Fox R, Freedman M, Galetta S, Goodman A, Guarnaccia J, Hashimoto S, Horowitz S, Javerbaum J, Kasper L, Kaufman M, Kerson L, Mass M, Rammohan K, Reiss M, Rolak L, Rose J, Scott T, Selhorst J, Shin R, Smith C, Stuart W, Thurston S, Wall M. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006 Mar 14; 66(5):678-84.
    View in: PubMed
  24. Giovannoni G, Goodman A. Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice? Neurology. 2005 Jul 12; 65(1):6-8.
    View in: PubMed
  25. Vollmer TL, Phillips JT, Goodman AD, Agius MA, Libonati MA, Giacchino JL, Grundy JS. An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis. Mult Scler. 2004 Oct; 10(5):511-20.
    View in: PubMed
  26. O'Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, Murray RS, Sheremata WA, Vollmer TL, Stone LA. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology. 2004 Jun 8; 62(11):2038-43.
    View in: PubMed
  27. Johnson KP, Brooks BR, Ford CC, Goodman AD, Lisak RP, Myers LW, Pruitt AA, Rizzo MA, Rose JW, Weiner LP, Wolinsky JS. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult Scler. 2003 Dec; 9(6):585-91.
    View in: PubMed
  28. Schwid SR, Tyler CM, Scheid EA, Weinstein A, Goodman AD, McDermott MP. Cognitive fatigue during a test requiring sustained attention: a pilot study. Mult Scler. 2003 Oct; 9(5):503-8.
    View in: PubMed
  29. Weinstock-Guttman B, Jacobs LD, Brownscheidle CM, Baier M, Rea DF, Apatoff BR, Blitz KM, Coyle PK, Frontera AT, Goodman AD, Gottesman MH, Herbert J, Holub R, Lava NS, Lenihan M, Lusins J, Mihai C, Miller AE, Perel AB, Snyder DH, Bakshi R, Granger CV, Greenberg SJ, Jubelt B, Krupp L, Munschauer FE, Rubin D, Schwid S, Smiroldo J. Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium. Mult Scler. 2003 Jun; 9(3):293-8.
    View in: PubMed
  30. Goodman AD, Mock DJ, Powers JM, Baker JV, Blumberg BM. Human herpesvirus 6 genome and antigen in acute multiple sclerosis lesions. J Infect Dis. 2003 May 1; 187(9):1365-76.
    View in: PubMed
  31. Ashton EA, Takahashi C, Berg MJ, Goodman A, Totterman S, Ekholm S. Accuracy and reproducibility of manual and semiautomated quantification of MS lesions by MRI. J Magn Reson Imaging. 2003 Mar; 17(3):300-8.
    View in: PubMed
  32. Calabresi PA, Austin H, Racke MK, Goodman A, Choyke P, Maloni H, McFarland HF. Impaired renal function in progressive multiple sclerosis. Neurology. 2002 Dec 10; 59(11):1799-801.
    View in: PubMed
  33. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Sandrock AW, Rudick RA, Simon JH, Simonian NA, Tsao EC, Whitaker JN. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 2002 Sep 10; 59(5):679-87.
    View in: PubMed
  34. Schwid SR, Goodman AD, McDermott MP, Bever CF, Cook SD. Quantitative functional measures in MS: what is a reliable change? Neurology. 2002 Apr 23; 58(8):1294-6.
    View in: PubMed
  35. Schwid SR, Covington M, Segal BM, Goodman AD. Fatigue in multiple sclerosis: current understanding and future directions. J Rehabil Res Dev. 2002 Mar-Apr; 39(2):211-24.
    View in: PubMed
  36. Goodman AD, Miller DH. Infections and MS: clinical trials move to center stage. Neurology. 2002 Jan 8; 58(1):7-8.
    View in: PubMed
  37. Hubinsky T, Cagan ER, Goodman A, Deitcher D, Page-Cook S, Cohen NL. Hearing the voice of the community above the din of the city: New York City Turning Point. J Public Health Manag Pract. 2002 Jan; 8(1):27-33.
    View in: PubMed
  38. Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol. 2001 Oct; 132(4):463-71.
    View in: PubMed
  39. Ito M, Blumberg BM, Mock DJ, Goodman AD, Moser AB, Moser HW, Smith KD, Powers JM. Potential environmental and host participants in the early white matter lesion of adreno-leukodystrophy: morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-mediated lipid antigen presentation. J Neuropathol Exp Neurol. 2001 Oct; 60(10):1004-19.
    View in: PubMed
  40. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Jak AJ, Kniker JE, Kooijmans MF, Lull JM, Sandrock AW, Simon JH, Simonian NA, Whitaker JN. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol. 2001 Jun; 58(6):961-7.
    View in: PubMed
  41. Wolinsky JS, Narayana PA, Johnson KP. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. Mult Scler. 2001 Feb; 7(1):33-41.
    View in: PubMed
  42. Schwid SR, Goodman AD, Apatoff BR, Coyle PK, Jacobs LD, Krupp LB, Miller AE, Wende KE, Brownscheidle CM. Are quantitative functional measures more sensitive to worsening MS than traditional measures? Neurology. 2000 Dec 26; 55(12):1901-3.
    View in: PubMed
  43. Ito M, Baker JV, Mock DJ, Goodman AD, Blumberg BM, Shrier DA, Powers JM. Human herpesvirus 6-meningoencephalitis in an HIV patient with progressive multifocal leukoencephalopathy. Acta Neuropathol. 2000 Sep; 100(3):337-41.
    View in: PubMed
  44. Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak RP, Myers LW, Panitch HS, Pruitt A, Rose JW, Kachuck N, Wolinsky JS. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler. 2000 Aug; 6(4):255-66.
    View in: PubMed
  45. Wolinsky JS, Narayana PA, Noseworthy JH, Lublin FD, Whitaker JN, Linde A, Gjörstrup P, Sullivan HC. Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators. Neurology. 2000 May 9; 54(9):1734-41.
    View in: PubMed
  46. Blumberg BM, Mock DJ, Powers JM, Ito M, Assouline JG, Baker JV, Chen B, Goodman AD. The HHV6 paradox: ubiquitous commensal or insidious pathogen? A two-step in situ PCR approach. J Clin Virol. 2000 May; 16(3):159-78.
    View in: PubMed
  47. Jacobs LD, Wende KE, Brownscheidle CM, Apatoff B, Coyle PK, Goodman A, Gottesman MH, Granger CV, Greenberg SJ, Herbert J, Krupp L, Lava NS, Mihai C, Miller AE, Perel A, Smith CR, Snyder DH. A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium. Mult Scler. 1999 Oct; 5(5):369-76.
    View in: PubMed
  48. Schwid SR, Thornton CA, Pandya S, Manzur KL, Sanjak M, Petrie MD, McDermott MP, Goodman AD. Quantitative assessment of motor fatigue and strength in MS. Neurology. 1999 Sep 11; 53(4):743-50.
    View in: PubMed
  49. Mock DJ, Powers JM, Goodman AD, Blumenthal SR, Ergin N, Baker JV, Mattson DH, Assouline JG, Bergey EJ, Chen B, Epstein LG, Blumberg BM. Association of human herpesvirus 6 with the demyelinative lesions of progressive multifocal leukoencephalopathy. J Neurovirol. 1999 Aug; 5(4):363-73.
    View in: PubMed
  50. Weinstein A, Schwid SR, Schiffer RB, McDermott MP, Giang DW, Goodman AD, Schwid SI. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol. 1999 Mar; 56(3):319-24.
    View in: PubMed
  51. Schwid SR, Goodman AD, Mattson DH, Mihai C, Donohoe KM, Petrie MD, Scheid EA, Dudman JT, McDermott MP. The measurement of ambulatory impairment in multiple sclerosis. Neurology. 1997 Nov; 49(5):1419-24.
    View in: PubMed
  52. Schwid SR, Goodman AD, Mattson DH. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b. Arch Neurol. 1997 Sep; 54(9):1169-90.
    View in: PubMed
  53. Schwid SR, Petrie MD, McDermott MP, Tierney DS, Mason DH, Goodman AD. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology. 1997 Apr; 48(4):817-21.
    View in: PubMed
  54. Schwid SR, Goodman AD, Puzas JE, McDermott MP, Mattson DH. Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol. 1996 Aug; 53(8):753-7.
    View in: PubMed
  55. Giang DW, Goodman AD, Schiffer RB, Mattson DH, Petrie M, Cohen N, Ader R. Conditioning of cyclophosphamide-induced leukopenia in humans. J Neuropsychiatry Clin Neurosci. 1996; 8(2):194-201.
    View in: PubMed
  56. Barned S, Goodman AD, Mattson DH. Frequency of anti-nuclear antibodies in multiple sclerosis. Neurology. 1995 Feb; 45(2):384-5.
    View in: PubMed
  57. Giang DW, Grow VM, Mooney C, Mushlin AI, Goodman AD, Mattson DH, Schiffer RB. Clinical diagnosis of multiple sclerosis. The impact of magnetic resonance imaging and ancillary testing. Rochester-Toronto Magnetic Resonance Study Group. Arch Neurol. 1994 Jan; 51(1):61-6.
    View in: PubMed
  58. Calabresi PA, Giang DW, Goodman AD. Progressive spinal multiple sclerosis. Semin Neurol. 1993 Dec; 13(4):322-32.
    View in: PubMed
  59. Mushlin AI, Detsky AS, Phelps CE, O'Connor PW, Kido DK, Kucharczyk W, Giang DW, Mooney C, Tansey CM, Hall WJ. The accuracy of magnetic resonance imaging in patients with suspected multiple sclerosis. The Rochester-Toronto Magnetic Resonance Imaging Study Group. JAMA. 1993 Jun 23-30; 269(24):3146-51.
    View in: PubMed
  60. Schiffer RB, Giang DW, Mushlin A, Ketonen L, Joy S, Kido D, Goodman AD, Mattson DH, Mooney C. Perils and pitfalls of magnetic resonance imaging in the diagnosis of multiple sclerosis. The Rochester-Toronto MRI Study Group. J Neuroimaging. 1993 Apr; 3(2):81-8.
    View in: PubMed
  61. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group. Ann Neurol. 1990 Jun; 27(6):591-605.
    View in: PubMed
  62. Goodman AD, Jacobson S, McFarland HF. Virus-specific cytotoxic T lymphocytes in multiple sclerosis: a normal mumps virus response adds support for a distinct impairment in the measles virus response. J Neuroimmunol. 1989 May; 22(3):201-9.
    View in: PubMed
  63. Gudesblatt M, Goodman AD, Rubenstein AE, Bender AN, Choi HS. Autonomic neuropathy associated with autoimmune disease. Neurology. 1985 Feb; 35(2):261-4.
    View in: PubMed

Visualizations


Goodman's Networks

Concepts
_
Co-Authors
_
Similar People
_
Same Department